Statin use in acute coronary syndromes: cellular mechanisms and clinical evidence

被引:25
作者
Rosenson, RS
Brown, AS
机构
[1] Northwestern Univ, Dept Med, Prevent Cardiol Ctr, Div Cardiol,Feinberg Sch Med, Chicago, IL 60611 USA
[2] Midw Heart Res Fdn, Naperville, IL USA
[3] Midw Heart Dis Prevent Ctr, Naperville, IL USA
[4] Northwestern Univ, Prevent Cardiol Ctr, Div Cardiol, Dept Prevent Med,Feinberg Sch Med, Chicago, IL 60611 USA
关键词
statins; acute coronary syndromes; unstable atherosclerotic plaque; endothelial function; inflammatory mediators;
D O I
10.1097/00041433-200212000-00005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Purpose of review Review the cellular mechanisms and clinical evidence for the use of statins in patients with unstable coronary syndromes. Recent findings Clinical trials of statin therapy in acute coronary syndromes demonstrate a rapid improvement in endothelial function, improved perfusion to ischemic myocardium, and an early reduction in cardiovascular events. The early benefit of statin therapy is related to a combination of molecular mechanisms that involve the oxidized LDL receptor (LOX-1), endothelial localized nitric oxide synthase, inflammatory cytokines, interstitial collagenases, and tissue factor expression. In human atheroma, 3 months' use of statin (pravastatin) therapy reduced the content of oxidized LDL, inflammatory cells (macrophage, T cells) infiltrates, and improved plaque stability by increasing the Collagen content of the fibrous cap. Summary The antiatherothrombotic effects of statin therapy appear to have important clinical relevance to patients with impaired myocardial perfusion and acute coronary syndrome.
引用
收藏
页码:625 / 630
页数:6
相关论文
共 52 条
[1]  
Aengevaeren WRM, 1997, CIRCULATION, V96, P429
[2]  
Aikawa M, 2001, CIRCULATION, V103, P276
[3]   Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction [J].
Al Suwaidi, J ;
Hamasaki, S ;
Higano, ST ;
Nishimura, RA ;
Holmes, DR ;
Lerman, A .
CIRCULATION, 2000, 101 (09) :948-954
[4]   THE EFFECT OF CHOLESTEROL-LOWERING AND ANTIOXIDANT THERAPY ON ENDOTHELIUM-DEPENDENT CORONARY VASOMOTION [J].
ANDERSON, TJ ;
MEREDITH, IT ;
YEUNG, AC ;
FREI, B ;
SELWYN, AP ;
GANZ, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (08) :488-493
[5]  
Andrews TC, 1997, CIRCULATION, V95, P324
[6]   Beneficial effects of Pravastatin (±colestyramine/niacin) initiated immediately after a coronary event (the randomized lipid-coronary artery disease [L-CAD] study) [J].
Arntz, HR ;
Agrawal, R ;
Wunderlich, W ;
Schnitzer, L ;
Stern, R ;
Fischer, F ;
Schultheiss, HP .
AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (12) :1293-1298
[7]  
Boyle JJ, 1997, J PATHOL, V181, P93, DOI 10.1002/(SICI)1096-9896(199701)181:1<93::AID-PATH696>3.0.CO
[8]  
2-H
[9]   HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis [J].
Bustos, C ;
Hernández-Presa, MA ;
Ortego, M ;
Tuñón, J ;
Ortega, L ;
Pérez, F ;
Díaz, C ;
Hernández, G ;
Egido, J .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (07) :2057-2064
[10]   Design of the Pravastatin or Atorvastation Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial [J].
Cannon, CP ;
McCabe, CH ;
Belder, R ;
Breen, J ;
Braunwald, E .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (07) :860-+